Trials / Terminated
TerminatedNCT00421421
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce The Risk of Acute Urinary Retention Relapse Following Successful Trial Without Catheter.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 276 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in patients who receive a 6 month treatment of dutasteride (0.5mg once daily) following a single episode of AUR followed by successful Trial Without Catheter compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride |
Timeline
- Start date
- 2007-03-01
- First posted
- 2007-01-12
- Last updated
- 2007-11-27
Locations
25 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00421421. Inclusion in this directory is not an endorsement.